Filter Results
:
(1,001)
Show Results For
-
All HBS Web
(1,001)
- People (4)
- News (249)
- Research (603)
- Events (7)
- Multimedia (24)
- Faculty Publications (389)
Show Results For
-
All HBS Web
(1,001)
- People (4)
- News (249)
- Research (603)
- Events (7)
- Multimedia (24)
- Faculty Publications (389)
- January 2003 (Revised May 2003)
- Case
Heineken NV: Workplace HIV/AIDS Programs in Africa (B)
Second in a three-part series that explores the multifaceted organizational and strategic choices that companies now face as a result of the global AIDS epidemic. Heineken is considering becoming one of the first companies to offer AIDS drugs (antiretroviral therapy)...
View Details
Keywords:
Health Disorders;
Corporate Social Responsibility and Impact;
Employees;
Food and Beverage Industry;
Africa
Barrett, Diana, and Daniella Ballou. "Heineken NV: Workplace HIV/AIDS Programs in Africa (B)." Harvard Business School Case 303-064, January 2003. (Revised May 2003.)
- October 1990 (Revised April 1991)
- Case
RU 486 (A)
Describes the factors faced by Roussel UCLAF, a French drug company, in deciding whether and how to market a controversial new drug, RU 486, which is often called "the French abortion pill." Roussel's decision involved its relations with the French government, its...
View Details
Keywords:
Judgments;
Ethics;
Product Launch;
Negotiation;
Outcome or Result;
Performance;
Business and Government Relations;
Health Industry;
Pharmaceutical Industry;
France;
Germany;
United States
Badaracco, Joseph L., Jr. "RU 486 (A)." Harvard Business School Case 391-050, October 1990. (Revised April 1991.)
- 30 Sep 2020
- News
How Nonprofit Foundations Can Sustainably Fund Disease Research
- 11 Apr 2019
- News
The DNA of Sustained Innovation
- May 2014 (Revised January 2015)
- Case
Vaxess Technologies, Inc.
By: John A. Quelch and Margaret L. Rodriguez
In February 2014, Michael Schrader, chief executive of Vaxess Technologies, Inc., was assessing the startup health care company's 2014 marketing plan. On December 31st, 2013, Vaxess had obtained an exclusive license to a series of patents for a silk protein technology...
View Details
Keywords:
Vaccine;
Cold Chain;
Antigen;
Temperature Controlled;
Developing Markets;
Immunization;
Health Care and Treatment;
Health Pandemics;
Global Strategy;
Supply Chain;
Health;
Health Industry;
Medical Devices and Supplies Industry
Quelch, John A., and Margaret L. Rodriguez. "Vaxess Technologies, Inc." Harvard Business School Case 514-107, May 2014. (Revised January 2015.)
- August 2004 (Revised July 2006)
- Case
PROPECIA TM: Helping Make Hair Loss History
By: Marta Wosinska and Youngme E. Moon
In late 1997, Tom Casola, brand manager for Propecia, debates the best approach to market this breakthrough one-a-day pill for hair loss. This launch would be atypical for a prescription drug because of the key position of the consumer. As a result, the team's...
View Details
Keywords:
Advertising;
Communication Strategy;
Customers;
Marketing Communications;
Marketing Strategy;
Product Launch;
Product;
Performance Effectiveness;
Problems and Challenges;
Quality;
Pharmaceutical Industry
Wosinska, Marta, and Youngme E. Moon. "PROPECIA TM: Helping Make Hair Loss History." Harvard Business School Case 505-035, August 2004. (Revised July 2006.)
- Working Paper
Rebates in the Pharmaceutical Industry: Evidence from Medicines Sold in Retail Pharmacies in the U.S.
By: Pragya Kakani, Michael Chernew and Amitabh Chandra
Rising list prices are often used to illustrate the burden of prescription drug spending, but payers routinely negotiate rebates from manufacturers that generate differences between list and net prices. List prices are easily available and affect patient cost-sharing,...
View Details
Keywords:
Pharmaceuticals;
Rebates;
Health Care and Treatment;
Markets;
Price;
Analysis;
Pharmaceutical Industry
Kakani, Pragya, Michael Chernew, and Amitabh Chandra. "Rebates in the Pharmaceutical Industry: Evidence from Medicines Sold in Retail Pharmacies in the U.S." NBER Working Paper Series, No. 26846, March 2020.
- September 2022
- Article
The Impact of Financial Assistance Programs on Health Care Utilization: Evidence from Kaiser Permanente
By: Alyce S. Adams, Raymond Kluender, Neale Mahoney, Jinglin Wang, Francis Wong and Wesley Yin
Most hospitals have financial assistance programs for low-income patients. We use administrative data from Kaiser Permanente to study the effects of financial assistance on health care utilization. Using a regression discontinuity design based on an income threshold...
View Details
Keywords:
Healthcare;
Utilization;
Financial Assistance;
Health Care and Treatment;
Social Issues;
Poverty;
Health Industry
Adams, Alyce S., Raymond Kluender, Neale Mahoney, Jinglin Wang, Francis Wong, and Wesley Yin. "The Impact of Financial Assistance Programs on Health Care Utilization: Evidence from Kaiser Permanente." American Economic Review: Insights 4, no. 3 (September 2022): 389–407.
- May 6, 2020
- Article
We Shouldn't Wait for a Breakthrough in the COVID-19 Pandemic
By: Gary P. Pisano
The ultimate solutions to the COVID-19 crisis may be big breakthroughs in building massive test and trace capacity and developing vaccines and drug remedies. But in the meantime, we should not ignore the potential cumulative impact of the many small things we already...
View Details
Pisano, Gary P. "We Shouldn't Wait for a Breakthrough in the COVID-19 Pandemic." Harvard Business Review Digital Articles (May 6, 2020).
- 2007
- Book
Perspectives on Risk and Regulation: The FDA at 100
By: Arthur A. Daemmrich and Joanna Radin
Perspectives on Risk and Regulation: The FDA at 100 brings together the viewpoints of Food and Drug Administration officials and industry leaders on the future of regulating food, drugs, medical devices, and dietary supplements. In a period of rapid scientific...
View Details
Keywords:
Private Sector;
Governing Rules, Regulations, and Reforms;
Policy;
Health Care and Treatment;
Business and Government Relations;
Risk and Uncertainty;
Cooperation
Daemmrich, Arthur A., and Joanna Radin, eds. Perspectives on Risk and Regulation: The FDA at 100. Chemical Heritage Foundation, 2007. (Fulltext.)
- January 2003 (Revised May 2003)
- Case
Heineken NV: Workplace HIV/AIDS Programs in Africa (A)
This case is the first in a three-part series that explores the multifaceted organizational and strategic choices that companies now face as a result of the global AIDS epidemic. Heineken is considering becoming one of the first companies to offer AIDS drugs...
View Details
Keywords:
Health Disorders;
Corporate Social Responsibility and Impact;
Employees;
Food and Beverage Industry;
Africa
Barrett, Diana, and Daniella Ballou. "Heineken NV: Workplace HIV/AIDS Programs in Africa (A)." Harvard Business School Case 303-063, January 2003. (Revised May 2003.)
- June 2016
- Case
Alnylam: Building a Biotechnology Powerhouse
By: Kevin Schulman
Alnylam is an early stage biomedical technology focused on commercial development of a novel technology platform, siRNA. This technology offered promise to treat rare genetic disorders that could not be treated with other technologies. Alnlyam's development entailed...
View Details
- February 2010 (Revised April 2010)
- Case
Organization and Strategy at Millennium (A)
By: Julie M. Wulf and Scott Waggoner
This case examines Millennium's strategic and organizational responses to the rapid evolution of the biopharmaceutical industry. In the early 2000s, as Millennium's competitive advantage in early-stage research slipped away and its losses mounted, founder and CEO Mark...
View Details
Keywords:
Transformation;
Leading Change;
Management Succession;
Organizational Change and Adaptation;
Competitive Strategy;
Competitive Advantage;
Biotechnology Industry;
Pharmaceutical Industry
Wulf, Julie M., and Scott Waggoner. "Organization and Strategy at Millennium (A)." Harvard Business School Case 710-415, February 2010. (Revised April 2010.)
- Forthcoming
- Article
Regulatory Incentives for Innovation: The FDA's Breakthrough Therapy Designation
By: Amitabh Chandra, Jennifer Kao, Kathleen L. Miller and Ariel Dora Stern
Regulators of new products confront a tradeoff between speeding a product to market and collecting additional product quality information. The FDA's Breakthrough Therapy Designation (BTD) provides an opportunity to understand if regulators can use new policy to...
View Details
Keywords:
Innovation and Invention;
Governing Rules, Regulations, and Reforms;
Government Administration;
Research and Development;
Pharmaceutical Industry
Chandra, Amitabh, Jennifer Kao, Kathleen L. Miller, and Ariel Dora Stern. "Regulatory Incentives for Innovation: The FDA's Breakthrough Therapy Designation." Review of Economics and Statistics (forthcoming). (Pre-published online March 18, 2024.)
- 10 Dec 2018
- News
Did Free Pens Cause the Opioid Crisis?
- Research Summary
Social Marketing and Cause Marketing
Rangan is studying the role of marketing in influencing social change by focusing on the adoption of social products and ideas such as family planning, economic development, drug abuse prevention, health care, and recycling. Rangan is attempting to determine how social...
View Details
- August 2018
- Article
The Impact of the Entry of Biosimilars: Evidence from Europe
By: Fiona M. Scott Morton, Ariel Dora Stern and Scott Stern
Biologics represent a substantial and growing share of the U.S. drug market. Traditional “small molecule” generics quickly erode the price and share of the branded product upon entry; however, only a few biosimilars have been approved in the U.S. since 2015, thereby...
View Details
Keywords:
Health Care;
Biosimilars;
Biologics;
Pharmaceutical Competition;
Healthcare Spending;
Innovation;
Health Care and Treatment;
Spending;
Market Entry and Exit;
Competition;
Innovation and Invention;
Pharmaceutical Industry;
United States;
Europe
Scott Morton, Fiona M., Ariel Dora Stern, and Scott Stern. "The Impact of the Entry of Biosimilars: Evidence from Europe." Review of Industrial Organization 53, no. 1 (August 2018): 173–210.
- February 2010
- Supplement
Organization and Strategy at Millennium (B)
By: Julie M. Wulf and Scott Waggoner
This case examines Millennium's strategic and organizational responses to the rapid evolution of the biopharmaceutical industry. In the early 2000s, as Millennium's competitive advantage in early-stage research slipped away and its losses mounted, founder CEO Mark...
View Details
Keywords:
Leading Change;
Transformation;
Decision Choices and Conditions;
Crisis Management;
Competitive Advantage;
Commercialization;
Selection and Staffing;
Product Development;
Organizational Change and Adaptation;
Pharmaceutical Industry
Wulf, Julie M., and Scott Waggoner. "Organization and Strategy at Millennium (B)." Harvard Business School Supplement 710-418, February 2010.
- April 1993 (Revised October 1995)
- Case
ALZA and Bio-Electro Systems (A): Technological and Financial Innovation
By: Josh Lerner and Peter Tufano
To develop the next generation of risky products, ALZA, a mature and profitable biotechnology firm specializing in drug delivery systems, must raise $40 million. Organizational constraints and competitive concerns demand that the work be done inside the firm. However,...
View Details
Keywords:
Risk and Uncertainty;
Technological Innovation;
Business Subsidiaries;
Decision Choices and Conditions;
Corporate Finance;
Biotechnology Industry;
Medical Devices and Supplies Industry
Lerner, Josh, and Peter Tufano. "ALZA and Bio-Electro Systems (A): Technological and Financial Innovation." Harvard Business School Case 293-124, April 1993. (Revised October 1995.)
- February 2000 (Revised October 2000)
- Case
Kendle International Inc.
By: Dwight B. Crane, Paul W. Marshall and Indra Reinbergs
Candace Kendle and Christopher Bergen, the CEO and COO of Kendle International, Inc., are reviewing ways to finance the growth of their privately-owned company. Kendle is a contract research organization that conducts clinical drug trials for pharmaceutical and...
View Details
Keywords:
Acquisition;
Financing and Loans;
Venture Capital;
Stock Options;
Banks and Banking;
Debt Securities;
International Finance;
Financial Strategy;
Management Skills;
Private Ownership;
Initial Public Offering;
Biotechnology Industry;
Pharmaceutical Industry
Crane, Dwight B., Paul W. Marshall, and Indra Reinbergs. "Kendle International Inc." Harvard Business School Case 200-033, February 2000. (Revised October 2000.)